Gout is a common and treatable form of inflammatory arthritis. Advances in gout management, particularly in the effective use of allopurinol and colchicine, help improve outcomes for New Zealanders with gout.
This video is a recording of the live webinar hosted by Mobile Health and presented by Professor Dalbeth on 14 March 2024. It is suitable for all primary care health professionals.
Professor Nicola Dalbeth discusses:
Professor Nicola Dalbeth is a specialist rheumatologist who holds dual appointments at Te
Whatu Ora (Te Toka Tumai-Auckland) and the University of Auckland. She leads a research
programme focusing on the mechanisms, impact, and treatment of gout. She has been
principal investigator of trials for novel therapeutic agents and treatment strategies in gout,
and has led international initiatives to define central concepts of the disease, including
nomenclature, staging, and response to treatment. She was a member of the core oversight
team for the 2020 American College of Rheumatology (ACR) Gout Management Guidelines.
This activity has been endorsed by The Royal New Zealand College of General Practitioners (RNZCGP) and has been approved for up to 1 CME credit for continuing professional development purposes (1 credit per learning hour). To claim your CPD credits, log in to your Te Whanake dashboard and record these activities under the appropriate learning category.
This activity has been endorsed by the PSNZ as suitable for inclusion in a pharmacist’s CE records for CPD purposes.
